Package 'CRM'

October 12, 2022

Title Continual Reassessmen	nt Method (CRM) for Phase I Clinical Trials		
Version 1.2.4			
Date 2018-9-25 Depends R (>= 2.10.0) Author Qianxing Mo Maintainer Qianxing Mo <qianxing.mo@moffitt.org> Description Functions for phase I clinical trials using the continual reassessment method.</qianxing.mo@moffitt.org>			
		LazyData no	
		License GPL (>= 2)	
		NeedsCompilation yes Repository CRAN Date/Publication 2018-09-26 16:10:02 UTC	
Inuca	· ·		
crm	A function for the continued reassessment method (CRM) used in Phase I clinical trials		
Description			
Function crm implemen clinical trials.	t the continued reassessment method (CRM) for dose finding in Phase I		
Usage			
crm(target,prior,pto	lata,model=1,a0=1,b=3)		

2 crm

Arguments

target Target probability of toxicity. The value must be in (0, 1).

prior Prior probabilities of toxicity for each dose. The values must be in (0,1) and in

an ascending order. For example, prior=c(0.05,0.1,0.2,0.3,0.5,0.7), which corre-

sponds to dose levels 1, 2, 3, 4, 5 and 6, respectively.

ptdata A n by 2 matrix in which the first column contains dose levels and the second

column contains toxicity indicators. Dose levels must be integers (e.g., 1, 2, 3, ..., N). Toxicity indicators must be 0 and 1, where 0 indicates no toxicity and 1

indicates toxicity.

model Dose-toxicity model. The value must be 1 (hyperbolic tangent model) or 2 (one-

parameter logistic model). Default is 1. Hyperbolic tangent model: \$p(y=1|x,a)

= $((\tanh(x)+1)/2)^a$ \$. One-parameter logistic model: $p(y=1|x,a,b) = \exp(b+ax)/(1+\exp(b+ax))$ \$.

For both models, y=1 indicates toxicity is observed; a is the parameter that can be updated based on the outcome of the trail; b is a fixed parameter. The prior

for a is exp(-a).

a0 Initial value for parameter a. Default is 1.0.

b A fixed parameter for the one-parameter logistic model. Default is 3.0.

Value

A list with the following two objects:

MTD The dose level proposed as the maximum tolerated dose (MTD) based on the

patient data

a The updated value for parameter a

Author(s)

```
Qianxing Mo; <qianxing.mo@moffitt.org>
```

References

John O'Quigley, Margaret Pepe, and Lloyd Fisher. (1990). Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer. *Biometrics*, 46, pp.33-48

See Also

```
crmsim, crmsiminc1, crmsiminc2
```

Examples

```
#The table 1 in O'Quingley et al.'s paper, page 40 
#This example is used to illustrate how the program is used to find 
#the MTD and the updated parameter 
target <- 0.2 
prior <- c(0.05, 0.1, 0.2, 0.3, 0.5, 0.7)
```

crmsim 3

crmsim

CRM Simulator

Description

crmsim, crmsiminc1 and crmsiminc2 implement the continued reassessment method (CRM) for dose finding in Phase I clinical trials. The operating characteristics of CRM are summarized through simulations.

crmsim allows users to select a variety of cohort sizes. A cohort of subjects are treated at the same dose

The cohort size is fixed to 1 in crmsiminc1 and crmsiminc2. crmsiminc1 implements an algorithm that allows a clinical trial to proceed to the next subject's dose assignment before observing the last subject's toxicity data. crmsiminc2 allows a clinical trial to proceed to the next subject's dose assignment before observing the last two subject's toxicity data (see Iasonos et al. for details).

Usage

Arguments

target

Target probability of toxicity. The value must be in (0, 1).

prior

Prior probabilities of toxicity for each dose. The values must be in (0,1) and in an ascending order. For example, prior=c(0.05,0.1,0.2,0.3,0.5,0.7), which corresponds to dose levels 1, 2, 3, 4, 5 and 6, respectively.

4 crmsim

true True probabilities of toxicity. The values must be in (0,1) and in an ascending

order. e.g. (0.1,0.2,0,3,0.4,0.5,0.8)

rate Recruitment/accrual rate of subjects in a 30 window. For example, if 1 subject

can be recruited per 30 days, then set rate = 1/30 = 0.033; if 2 patients per 30

day then rate = 2/30 = 0.0667.

cycle The length of treatment cycle in days.

cohort Cohort size of subjects entering into the trials. Default is 1. The value for cohort

must be less than or equal to the value for nsubject.

nsubject Total number of subjects in one simulation(or trial). Default is 24. nsubject

should be equal to n*cohort, where n is positive integer.

nsim Total number of simulations. Default is 1000.

model Dose-toxicity model. The value must be 1 (hyperbolic tangent model) or 2 (one-

parameter logistic model). Default is 1. Hyperbolic tangent model: p(y=1|x,a)

= $((\tanh(x)+1)/2)^a$ \$. One-parameter logistic model: $p(y=1|x,a,b) = \exp(b+ax)/(1+\exp(b+ax))$ \$.

For both models, y=1 indicates toxicity is observed; a is the parameter that can be updated based on the outcome of the trail; b is a fixed parameter. The prior

for a is exp(-a).

a0 Initial value for parameter a. Default is 1.0.

b A fixed parameter for the one-parameter logistic model. Default is 3.0.

jump=FALSE means NOT allowing that the proposed dose by the CRM program

has an increase of more than one level than the previous level; jump=TRUE means allowing more-than-one-level increase of the proposed dose by the CRM

program.

start.dose Initial dose for each trial. Default is 1.

seed Seed for the random number generator. Default is 777.

Value

SimResult is a matrix that summarizes the operating characteristics of CRM. The column names are the dose levels. The row names are the operating characteristics.

% Selection the percentage of selection of each dose as MTD

% Subjects Treated

the percentage of subjects treated at each dose

Subjects Treated

the average number of subjects treated at each dose

Average Toxicities

the average toxicities per trial at each dose

True Probabilities

the true probability of toxicity of each dose

TrialDuration is a table that summarizes the time needed for the trial based on the simulation.

Author(s)

Qianxing Mo; <qianxing.mo@moffitt.org>

crmsim 5

References

John O'Quigley, Margaret Pepe, and Lloyd Fisher. (1990). Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer. *Biometrics*, 46, pp.33-48

Alexia Iasonos, Andrew S Wilton, Elyn R Riedel, Venkatraman E Seshan and David R Spriggs. A comprehensive comparison of the continual reassessment method to the standard 3+3 dose escalation scheme in Phase I dose-finding studies. *Clinical Trials*, 2008, nil:1-12

See Also

crm

Examples

```
prior1 <- c(0.05, 0.1, 0.2, 0.3, 0.5, 0.7)
true1 <- c(0.1, 0.15, 0.2, 0.4, 0.5, 0.8)
### simulations using model 1 (hyperbolic tangent model)
### uncomment the following code to run ###
#crmsim(target=0.2,prior=prior1,true=true1,rate=0.1,cycle=21,cohort=1,nsubject=24,nsim=1000,
        model=1,a0=1,b=3,jump=FALSE,start.dose=1,seed=777)
#crmsiminc1(target=0.2,prior=prior1,true=true1,rate=0.1,cycle=21,nsubject=24,nsim=1000,
            model=1,a0=1,b=3,jump=FALSE,start.dose=1,seed=777)
#crmsiminc2(target=0.2,prior=prior1,true=true1,rate=0.1,cycle=21,nsubject=24,nsim=1000,
            model=1,a0=1,b=3,jump=FALSE,start.dose=1,seed=777)
# simulations using model 2 (one-parameter logistic model)
#crmsim(target=0.2,prior=prior1,true=true1,rate=0.1,cycle=21,cohort=1,nsubject=24,nsim=1000,
        model=2,a0=1,b=3,jump=FALSE,start.dose=1,seed=777)
#crmsiminc1(target=0.2,prior=prior1,true=true1,rate=0.1,cycle=21,nsubject=24,nsim=1000,
            model=2,a0=1,b=3,jump=FALSE,start.dose=1,seed=777)
#crmsiminc2(target=0.2,prior=prior1,true=true1,rate=0.1,cycle=21,nsubject=24,nsim=1000,
            model=2,a0=1,b=3,jump=FALSE,start.dose=1,seed=777)
```

Index

```
* design
crm, 1
crmsim, 3

crm, 1, 5
crmsim, 2, 3
crmsiminc1, 2
crmsiminc2, 2
crmsiminc2 (crmsim), 3
```